HANSOH PHARMAC. HD-00001 (3KY) - Net Assets
Based on the latest financial reports, HANSOH PHARMAC. HD-00001 (3KY) has net assets worth €35.36 Billion EUR (≈ $41.34 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€39.90 Billion ≈ $46.65 Billion USD) and total liabilities (€4.54 Billion ≈ $5.30 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See debt-free asset ratio of HANSOH PHARMAC. HD-00001 to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €35.36 Billion |
| % of Total Assets | 88.63% |
| Annual Growth Rate | 15.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.69 |
HANSOH PHARMAC. HD-00001 - Net Assets Trend (2021–2025)
This chart illustrates how HANSOH PHARMAC. HD-00001's net assets have evolved over time, based on quarterly financial data. Also explore HANSOH PHARMAC. HD-00001 annual equity growth to track the company's year-over-year net asset growth rate.
Annual Net Assets for HANSOH PHARMAC. HD-00001 (2021–2025)
The table below shows the annual net assets of HANSOH PHARMAC. HD-00001 from 2021 to 2025. For live market cap and overall valuation, see HANSOH PHARMAC. HD-00001 (3KY) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €35.36 Billion ≈ $41.34 Billion |
+23.31% |
| 2024-12-31 | €28.68 Billion ≈ $33.53 Billion |
+11.18% |
| 2023-12-31 | €25.79 Billion ≈ $30.16 Billion |
+13.90% |
| 2022-12-31 | €22.65 Billion ≈ $26.48 Billion |
+13.07% |
| 2021-12-31 | €20.03 Billion ≈ $23.42 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HANSOH PHARMAC. HD-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1655413800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €16.55 Billion | 46.81% |
| Other Components | €18.81 Billion | 53.19% |
| Total Equity | €35.36 Billion | 100.00% |
HANSOH PHARMAC. HD-00001 Competitors by Market Cap
The table below lists competitors of HANSOH PHARMAC. HD-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Erste Bank Polska S.A.
WAR:EBP
|
$22.08 Billion |
|
Pure Storage Inc
NYSE:PSTG
|
$22.11 Billion |
|
Sany Heavy Industry Co Ltd
SHG:600031
|
$22.12 Billion |
|
Loews Corp
NYSE:L
|
$22.17 Billion |
|
EnBW Energie Baden-Württemberg AG
XETRA:EBK
|
$22.06 Billion |
|
STD BK GRP SP.ADRS RC-10
F:SKCS
|
$22.06 Billion |
|
Incyte Corporation
NASDAQ:INCY
|
$22.02 Billion |
|
Bayan Resources Tbk
JK:BYAN
|
$21.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HANSOH PHARMAC. HD-00001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,679,914,000 to 35,364,451,000, a change of 6,684,537,000 (23.3%).
- Net income of 5,555,461,000 contributed positively to equity growth.
- Dividend payments of 2,012,184,000 reduced retained earnings.
- New share issuances of 3,588,683,000 increased equity.
- Other factors decreased equity by 447,423,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.56 Billion | +15.71% |
| Dividends Paid | €2.01 Billion | -5.69% |
| Share Issuances | €3.59 Billion | +10.15% |
| Other Changes | €-447.42 Million | -1.27% |
| Total Change | €- | 23.31% |
Book Value vs Market Value Analysis
This analysis compares HANSOH PHARMAC. HD-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.05x to 0.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.38 | €3.54 | x |
| 2022-12-31 | €3.83 | €3.54 | x |
| 2023-12-31 | €4.35 | €3.54 | x |
| 2024-12-31 | €4.83 | €3.54 | x |
| 2025-12-31 | €5.84 | €3.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HANSOH PHARMAC. HD-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.71%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 36.97%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.13x
- Recent ROE (15.71%) is above the historical average (13.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 13.54% | 27.31% | 0.37x | 1.36x | €710.02 Million |
| 2022 | 11.41% | 27.54% | 0.31x | 1.32x | €319.05 Million |
| 2023 | 12.71% | 32.44% | 0.31x | 1.28x | €698.03 Million |
| 2024 | 15.24% | 35.66% | 0.39x | 1.10x | €1.50 Billion |
| 2025 | 15.71% | 36.97% | 0.38x | 1.13x | €2.02 Billion |
Industry Comparison
This section compares HANSOH PHARMAC. HD-00001's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,862,356,536
- Average return on equity (ROE) among peers: -42.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HANSOH PHARMAC. HD-00001 (3KY) | €35.36 Billion | 13.54% | 0.13x | $22.06 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $48.38 Billion | 9.77% | 0.93x | $1.27 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $4.11 Billion | 11.00% | 0.48x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $110.37 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-9.91 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $29.16 Million | -49.27% | 0.13x | $6.62 Million |
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more